347 related articles for article (PubMed ID: 27237441)
1. Nuclear Medicine in Pediatric and Adolescent Tumors.
Kiratli PÖ; Tuncel M; Bar-Sever Z
Semin Nucl Med; 2016 Jul; 46(4):308-23. PubMed ID: 27237441
[TBL] [Abstract][Full Text] [Related]
2. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.
Bleeker G; Tytgat GA; Adam JA; Caron HN; Kremer LC; Hooft L; van Dalen EC
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009263. PubMed ID: 26417712
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study.
Piccardo A; Lopci E; Conte M; Garaventa A; Foppiani L; Altrinetti V; Nanni C; Bianchi P; Cistaro A; Sorrentino S; Cabria M; Pession A; Puntoni M; Villavecchia G; Fanti S
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):57-71. PubMed ID: 21932116
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy.
Dhull VS; Sharma P; Patel C; Kundu P; Agarwala S; Bakhshi S; Bhatnagar V; Bal C; Kumar R
Nucl Med Commun; 2015 Oct; 36(10):1007-13. PubMed ID: 26049371
[TBL] [Abstract][Full Text] [Related]
6. Guidelines on nuclear medicine imaging in neuroblastoma.
Bar-Sever Z; Biassoni L; Shulkin B; Kong G; Hofman MS; Lopci E; Manea I; Koziorowski J; Castellani R; Boubaker A; Lambert B; Pfluger T; Nadel H; Sharp S; Giammarile F
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):2009-2024. PubMed ID: 29938300
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET/CT in pediatric solid tumors.
Franzius C
Q J Nucl Med Mol Imaging; 2010 Aug; 54(4):401-10. PubMed ID: 20823808
[TBL] [Abstract][Full Text] [Related]
8. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
[TBL] [Abstract][Full Text] [Related]
9. PET/CT in pediatric oncology.
Samuel AM
Indian J Cancer; 2010; 47(4):360-70. PubMed ID: 21131747
[TBL] [Abstract][Full Text] [Related]
10. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients.
Kushner BH; Yeung HW; Larson SM; Kramer K; Cheung NK
J Clin Oncol; 2001 Jul; 19(14):3397-405. PubMed ID: 11454888
[TBL] [Abstract][Full Text] [Related]
11. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of ¹⁸F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma.
Piccardo A; Puntoni M; Lopci E; Conte M; Foppiani L; Sorrentino S; Morana G; Naseri M; Cistaro A; Villavecchia G; Fanti S; Garaventa A
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1046-56. PubMed ID: 24562643
[TBL] [Abstract][Full Text] [Related]
13. Nuclear medicine studies of the prostate, testes, and bladder.
Jana S; Blaufox MD
Semin Nucl Med; 2006 Jan; 36(1):51-72. PubMed ID: 16356796
[TBL] [Abstract][Full Text] [Related]
14. The use of gallium-68 labeled somatostatin receptors in PET/CT imaging.
Ambrosini V; Nanni C; Fanti S
PET Clin; 2014 Jul; 9(3):323-9. PubMed ID: 25030395
[TBL] [Abstract][Full Text] [Related]
15. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
Dimitrakopoulou-Strauss A; Strauss L
Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
[TBL] [Abstract][Full Text] [Related]
16. PET/CT imaging in neuroblastoma.
Piccardo A; Lopci E; Conte M; Foppiani L; Garaventa A; Cabria M; Villavecchia G; Fanti S; Cistaro A
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):29-39. PubMed ID: 23474633
[TBL] [Abstract][Full Text] [Related]
17. The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy.
Piccardo A; Treglia G; Fiz F; Bar-Sever Z; Bottoni G; Biassoni L; Borgwardt L; de Keizer B; Jehanno N; Lopci E; Kurch L; Massollo M; Nadel H; Roca Bielsa I; Shulkin B; Vali R; De Palma D; Cecchin D; Santos AI; Zucchetta P
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):756-767. PubMed ID: 37962616
[TBL] [Abstract][Full Text] [Related]
18. Is there a role for PET-CT and SPECT-CT in pediatric oncology?
Biermann M; Schwarzlmüller T; Fasmer KE; Reitan BC; Johnsen B; Rosendahl K
Acta Radiol; 2013 Nov; 54(9):1037-45. PubMed ID: 23319723
[TBL] [Abstract][Full Text] [Related]
19. Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments.
Samim A; Tytgat GAM; Bleeker G; Wenker STM; Chatalic KLS; Poot AJ; Tolboom N; van Noesel MM; Lam MGEH; de Keizer B
J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33916640
[TBL] [Abstract][Full Text] [Related]
20. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
